RBC increased its price target for Viridian Therapeutics to $41, up from $38.

Nov 5, 2026, 2:33 PM ETOpinionRead the original at marketscreener.com

Good for VRDN

RBC raised its target and kept its Outperform rating, giving VRDN a favorable analyst view. RBC also flagged speculative risk, and this report gives no new company results.

VRDN · Viridian Therapeutics, Inc.

AI read · Good for VRDN

The AI's read

For Viridian, this is a positive signal about RBC's view of its shares, not a new result from the business. RBC also noted speculative risk, and the story gives no details from the third-quarter report, so the signal is limited.

Get alerts for VRDN

Follow Viridian Therapeutics, Inc. (VRDN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VRDN

Free on the App Store and Google Play, or on the web.